Unlock stock picks and a broker-level newsfeed that powers Wall Street.
OTC Markets OTCPK - Delayed Quote USD

Xvivo Perfusion AB (publ) (XVIPF)

Compare
28.94
0.00
(0.00%)
At close: April 2 at 4:00:00 PM EDT
Loading Chart for XVIPF
  • Previous Close 0.00
  • Open 39.53
  • Bid 28.12 x 43500
  • Ask 28.65 x 40000
  • Day's Range 39.53 - 39.53
  • 52 Week Range 26.38 - 52.38
  • Volume 100
  • Avg. Volume 127
  • Market Cap (intraday) 911.533M
  • Beta (5Y Monthly) 2.08
  • PE Ratio (TTM) 53.59
  • EPS (TTM) 0.54
  • Earnings Date Apr 22, 2025 - Apr 28, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.

www.xvivogroup.com

170

Full Time Employees

December 31

Fiscal Year Ends

Recent News: XVIPF

View More

Performance Overview: XVIPF

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

XVIPF
29.59%
OMX Stockholm 30 Index (^OMX)
2.93%

1-Year Return

XVIPF
9.70%
OMX Stockholm 30 Index (^OMX)
4.11%

3-Year Return

XVIPF
22.62%
OMX Stockholm 30 Index (^OMX)
13.71%

5-Year Return

XVIPF
187.82%
OMX Stockholm 30 Index (^OMX)
71.60%

Compare To: XVIPF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: XVIPF

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    890.20M

  • Enterprise Value

    852.10M

  • Trailing P/E

    53.43

  • Forward P/E

    53.48

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    11.19

  • Price/Book (mrq)

    4.25

  • Enterprise Value/Revenue

    10.38

  • Enterprise Value/EBITDA

    96.58

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.94%

  • Return on Assets (ttm)

    2.40%

  • Return on Equity (ttm)

    8.40%

  • Revenue (ttm)

    822.41M

  • Net Income Avi to Common (ttm)

    172.18M

  • Diluted EPS (ttm)

    0.54

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    415.52M

  • Total Debt/Equity (mrq)

    1.58%

  • Levered Free Cash Flow (ttm)

    -125.03M

Research Analysis: XVIPF

View More

Company Insights: XVIPF

Research Reports: XVIPF

View More

People Also Watch